Showing results (31-40 of 54) with videos related to

Sort By:
Pageof 6
European Journal of Haematology|October 8, 2022
Non-driver gene mutation analysis in a large cohort of polycythemia vera and essential thrombocythemiaSoji Morishita, Yoshinori Hashimoto, Chiho Furuya, et al.
Plos One|August 22, 2014
Detection of MPLW515L/K mutations and determination of allele frequencies with a single-tube PCR assayHiraku Takei, Soji Morishita, Marito Araki, et al.
Experimental Hematology|December 13, 2022
Establishment of isogenic induced pluripotent stem cells with or without pathogenic mutation for understanding the pathogenesis of myeloproliferative neoplasmsChang Liu, Misa Imai, Yoko Edahiro, et al.
Oncotarget|May 4, 2018
Hypoxia-inducible factor-2 alpha up-regulates CD70 under hypoxia and enhances anchorage-independent growth and aggressiveness in cancer cellsShojiro Kitajima, Kian Leong Lee, Masaki Fujioka, et al.
European Journal of Haematology|February 7, 2018
The 2014 BCSH criteria and the 2016 WHO criteria for essential thrombocythemia: A comparison in a large-scale cohortTomonori Ochiai, Hajime Yasuda, Marito Araki, et al.
Leukemia|June 28, 2018
Homomultimerization of mutant calreticulin is a prerequisite for MPL binding and activationMarito Araki, Yinjie Yang, Misa Imai, et al.
Oncotarget|February 1, 2018
Hypoxia-inducible factor-1α promotes cell survival during ammonia stress response in ovarian cancer stem-like cellsShojiro Kitajima, Kian Leong Lee, Hiroki Hikasa, et al.
Cancer Medicine|July 1, 2022
Clinical features of acquired erythrocytosis: Low levels of serum erythropoietin in a subset of non-neoplastic erythrocytosis patientsYosuke Mori, Marito Araki, Soji Morishita, et al.
Blood|January 29, 2016
Activation of the thrombopoietin receptor by mutant calreticulin in CALR-mutant myeloproliferative neoplasmsMarito Araki, Yinjie Yang, Nami Masubuchi, et al.
Clinical Pharmacology in Drug Development|December 30, 2022
Phase 1 Clinical Trial of PPMX-T003, a Novel Human Monoclonal Antibody Specific for Transferrin Receptor 1, to Evaluate Its Safety, Pharmacokinetics, and PharmacodynamicsYoichiro Ogama, Yuji Kumagai, Norio Komatsu, et al.
Pageof 6